- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
FEI Company (Nasdaq: FEIC) will release its financial results for the third quarter of 2007 after the financial markets close on Tuesday, October 30, 2007. The third quarter ended on September 30, 2007.
A conference call and simultaneous webcast to discuss the results will be held on Tuesday, October 30 at 2:00 p.m. PDT (5:00 p.m. EDT). Access to the call will be available at 1-800-257-7087 (U.S., toll-free) or 1-303-205-0044 (international), with the conference title: FEI Q3 Earnings Call. A telephone replay of the call will be available at 1-800-405-2236 (U.S.) or 1-303-590-3000 (international) with the passcode: 11099156#. Both a live and recorded audio webcast of the call will be available at the investor relations section of the company's web site at http://www.fei.com .
About FEI Company
FEI Company is a global leader in providing innovative instruments for nanoscale imaging, analysis and prototyping. FEI focuses on delivering solutions that provide groundbreaking results and accelerate research, development and manufacturing cycles for its customers in Semiconductor and Data Storage, Academic and Industrial R&D, and Life Sciences markets. With R&D centers in North America and Europe, and sales and service operations in more than 50 countries around the world, FEI's Tools for Nanotech(TM) are bringing the nanoscale within the grasp of leading researchers and manufacturers.
For more information, please click here
Treasurer and Investor Relations Director
Copyright © FEI CompanyIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Newly discovered 'design rule' brings nature-inspired nanostructures one step closer: Computer sims and microscopy research at Berkeley Lab yield first atomic-resolution structure of a peptoid nanosheet October 8th, 2015
Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015